Independent Investigation Appointment
SkinBioTherapeutics plc has appointed Alyson Levett, its new Non-Executive Director and Chair of the Audit Committee, to oversee an ongoing investigation, supported by FRP Advisory undertaking an independent forensic review. This action aims to expedite the investigation and allow for the timely release of HY results, ensuring all identified issues are addressed before the senior leadership team can refocus on business growth.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
20 February 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that it has appointed its new Non-Executive Director and Chair of the Audit Committee, Alyson Levett, to oversee the continuing investigation process on behalf of the Board. It has also appointed FRP Advisory to undertake an independent, forensic review into the matters outlined by the Company on Monday, 16 February. Existing external legal and professional advisers will also support the process, as necessary.
Alyson Levett, Non-Executive Director and Chair of the Audit Committee of SkinBioTherapeutics, said: "The Board's aim has always been to act quickly - undertaking an investigation whilst maintaining business continuity and minimising disruption. FRP Advisory can help us expedite our investigation and enable us to issue the HY results as soon as possible in the confidence that all issues have been identified. The senior leadership team can then return their focus to running and growing the business."
The Company will continue to provide updates as appropriate.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.